demonstrated that KRAS mutations were present in 44.2% of colorectal cancers and 37.1% of rectal cancers and were not present in gastric cancers.39 Similarly, in a study by Koulouridi et al., KRAS mutations were found in 93.2% of patients, with the KRAS G12D subtype (30.1%) being the most prevalent.40 This evidence concerns the gene KRAS and rectal cancer.